NewAmsterdam Pharma Company N.V. (NAMS) Stock Score, Valuation & Financial Research
NewAmsterdam Pharma Company N.V. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 25/100.
Quick answer for NAMS
NewAmsterdam Pharma Company N.V. currently has a Wall Street Score of 25/100. The stored market price is $22.36. Its financial score is 46/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What NewAmsterdam Pharma Company N.V. does
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
NAMS financial snapshot
- Wall Street Score:
- 25/100
- Current price:
- $22.36
- Market capitalization:
- $2.61B
- Revenue:
- $22.6M
- Net income:
- $-212.7M
- Free cash flow:
- $-148.0M
- Cash:
- $457.6M
- Total debt:
- $23K
- EPS:
- -1.75
- Financial score:
- 46/100
- Valuation score:
- 0/100
- Revenue score:
- 20/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $-148.0M, showing cash burn in the current stored period.
- The balance sheet shows $457.6M of cash versus $23K of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 46/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research NAMS
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.